Facebook Pixel Can India Reclaim API Throne from China? | Bio Spectrum - business - Read this story on Magzter.com

Try GOLD - Free

Can India Reclaim API Throne from China?

Bio Spectrum

|

September 2024

Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).

Can India Reclaim API Throne from China?

India is the source of around 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs. However, India imports about 70 per cent of its APIs from China as it's a cheaper option than manufacturing them domestically. There were 58 APIs in which India was heavily dependent on China. In the case of 45 APIs, India was dependent on China for 100 per cent of imports. Out of these 58 APIs, 29 APIs are manufactured through fermentation and 29 APIs are manufactured through chemical synthesis. The Department of Pharmaceuticals has drawn up a list of 56 APIs to prioritise them for the Make-in-India initiative. These include APIs or bulk drugs that go into the making of essential drugs, such as antibiotics, anti-HIV medicines, and the humble but indispensable paracetamol. The plan to make APIs in India has been in the works for some time but the Council of Scientific and Industrial Research (CSIR was engaged only recently. Let's see how these steps taken by the government help to promote the production of KSMS and APIs in India in the coming years.

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Bio Spectrum

Can India's CDMOS Lead the Next Biopharma Wave?

India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).

time to read

8 mins

March 2026

Bio Spectrum

Bio Spectrum

Telangana turns catalyst for innovation

Telangana is at a pivotal moment in its journey as a global life sciences hub.

time to read

6 mins

March 2026

Bio Spectrum

Bio Spectrum

Is AI the New Weapon in the Fight to End TB?

A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).

time to read

2 mins

March 2026

Bio Spectrum

Bio Spectrum

ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India

US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy

Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"

Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer

Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Haleon ropes in Kedar Lele as President for India Subcontinent

Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Centre revises Startup Recognition Framework to strengthen Startup India Action Plan

The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"

In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.

time to read

5 mins

March 2026

Listen

Translate

Share

-
+

Change font size